Chloroquine Protects Against Zika In Vitro

The antimalarial drug reduces the number of infected Vero and human brain microvascular endothelial cells—among other cell types—in culture, researchers report in a preprint.

Written byMarcia Triunfol
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

WIKIMEDIA, BENJAH-BMM27 Chloroquine, a 4-aminoquinoline, is a weak base with anti-inflammatory proprieties already used to prevent and treat malaria. The drug has protective effects against dengue infection in monkeys and inhibits replication of the virus in infected Vero cells. According to researchers in Brazil, chloroquine appears to also protect against Zika virus infection in various cell types in vitro. The team published its results last week (May 2) in a bioRxiv preprint.

Amilcar Tanuri at the Federal University of Rio de Janeiro and colleagues tested the effects of chloroquine in different Zika virus–infected cell types, observing each culture for five days. Flow cytometry and immunofluorescence staining revealed that chloroquine at 25 and 50 μM reduced the number of Zika-infected Vero cells by 65 percent and 95 percent, respectively. When tested in human brain microvascular endothelial cells (hBMEC), which are often used to model the blood-brain barrier, chloroquine protected 80 percent of the cells examined from Zika-induced death, the researchers reported.

“Chloroquine . . . is not an antiviral drug as it acts on the cell and not on the virus,” Tanuri told The Scientist.

Zika is known to target neurospheres and brain organoids; viral infection is associated ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies